title: Autologous peripheral blood stem cell transplantation following heart transplantation for primary systemic amyloidosis.
abstract: A 47 years old woman was admitted with severe congestive heart failure. Cardiac echography showed increased intra-ventricular septum thickness, and there was a serum Ig G lambda monoclonal component. Cardiac biopsies confirmed diffuse amyloidosis of Al type. To avoid cardiac toxicity of chemotherapy, the patient received first a heart transplantation (HT), followed six months later by melphalan 200 mg/m(2) and autologous peripheral blood stem cell support (PBSCT). This case suggests that such strategy is feasible with a favorable outcome, and HT may be an appropriate procedure for some patients with Al amyloidosis who meet the criteria for PBSCT.
authors.affiliation: Hematology and Medical Oncology Department, CHU de Montpellier, Hôpital Lapeyronie, 34295 Montpellier Cedex 05, France.
authors.forename: M
authors.initials: M
authors.lastname: Mohty
authors.forename: B
authors.initials: B
authors.lastname: Albat
authors.forename: N
authors.initials: N
authors.lastname: Fegueux
authors.forename: J F
authors.initials: JF
authors.lastname: Rossi
mesh_terms: D000686:Amyloidosis / Q000628:therapy*; D017809:Fatal Outcome; D005260:Female; D006333:Heart Failure / Q000209:etiology / Q000628:therapy; D016027:Heart Transplantation; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D014182:Transplantation, Autologous
chemical_list: D008558:Melphalan